[The application efficacy of immunomodulators in complex of treatment of an acute necrotic pancreatitis].
Kopchak. V M VM; Khomiak. I V IV; Stasenko. A A AA; Todurov. I M IM; Kopchak. K V KV
Key Findings
- Thymalin was added to standard care for acute necrotic pancreatitis
- 66.7% of patients showed disease regression
- All patients survived despite the severity of the condition
Practical Outcomes
- The data hint that thymalin might help the immune response in serious pancreatic inflammation, but the study is tiny, uncontrolled, and focused on a hospital setting. For self‑experimenters, there’s not enough evidence to adopt it for general health or longevity purposes.
Summary
A tiny study of 18 people with severe pancreas inflammation used the peptide thymalin as part of a treatment mix. About two‑thirds got better without surgery, a few developed cysts, and the rest needed an operation, but everyone survived.
Abstract
Analysis of efficacy of the immunomodulators application, thymalin in particular, in complex treatment algorhythm in 18 patients with an acute necrotic pancreatitis was conducted. Efficacy of immunocorrecting therapy in the immune state improvement, purulent-septic complications prophylaxis, the abortive course of the disease promotion was established In 12 (66.7) patients the disease regression was noted, in 2 (11.1%)--the inflammatory process delineation with pancreatic pseudocyst formation was observed, 4 (22.2%) patients were operated on. All the patients survived.
Study Information
pubmed
2004